I am a breastfeeding mother and i want to know if it is safe to use Moclobemidum? Is Moclobemidum safe for nursing mother and child? Does Moclobemidum extracts into breast milk? Does Moclobemidum has any long term or short term side effects on infants? Can Moclobemidum influence milk supply or can Moclobemidum decrease milk supply in lactating mothers?
- DrLact safety Score for Moclobemidum is 1 out of 8 which is considered Safe as per our analyses.
- A safety Score of 1 indicates that usage of Moclobemidum is mostly safe during lactation for breastfed baby.
- Our study of different scientific research also indicates that Moclobemidum does not cause any serious side effects in breastfeeding mothers.
- Most of scientific studies and research papers declaring usage of Moclobemidum safe in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Excreted into breast milk in a clinically non-significant amount. No clinical untoward effects on the physical and psychomotor development of the infants at both short and long-term basis. Some reports of galactorrhea have been described. Because there is less published experience with this drug than with others, an alternative known to be safer should be preferred mostly during the neonatal period or prematurity.
Moclobemidum is not approved for marketing in the United States by the U.S. Food and Drug Administration, but is available in other countries. Limited information indicates that maternal doses of Moclobemidum up to 900 mg daily produce low levels in milk. Although several breastfed infants apparently experienced no adverse effects during maternal use of Moclobemidum, no rigorous, long-term data are available. Until more data are available, Moclobemidum should only be used with careful monitoring during breastfeeding, especially while nursing a newborn or preterm infant.
Nine women were being treated for postpartum depression with Moclobemidum in daily dosages ranging from 150 mg to 900 mg. All breastfed (extent not stated) their infants during therapy, but the duration of infant exposure to Moclobemidum in breastmilk was not stated. Maternal reports of infant weight gain, milestones and behavioral effects as well as clinical observation by the authors indicted no adverse effects in the breastfed infants.[2] Four women who took Moclobemidum in dosages of 300 mg to 1200 mg daily during pregnancy were followed up in the neonatal period and at 1 year postpartum. All women breastfed (extent not stated) their infants. One woman ceased breastfeeding at 2 months postpartum because of severe gastroesophageal reflux in the infant; two other mothers breastfed beyond 12 months. The duration of breastfeeding in the fourth infant was not sated. All infants achieved developmental milestones.[3]
Moclobemidum increases serum prolactin in males[4][5][6] and has caused galactorrhea in women.[7] The prolactin level in a mother with established lactation may not affect her ability to breastfeed.
Disclaimer:
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.